Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

Our round-up of #financings in the biotech arena this week is led by a $125 million Series A for #AmbrosTherapeutics, a start-up formed to develop a drug for a rare #paindisorder that is already on the market in Italy.